Author: claimsbot

1. A method for accelerating a plant growth by using a compound represented by formula (1) as an active ingredient for accelerating a plant growth:
wherein R1 and R2 each independently represent a C1-4 alkyl group; Y represents a hydrogen atom, a halogeno group, a C1-4 alkyl group, or a C1-4 haloalkyl group; each R3 independently represents a halogeno group, a cyano group, a nitro group, a C1-4 alkyl group, or a C1-4 haloalkyl group; and n represents the number of R3 and is an integer of 0 to 6.
2. A method for accelerating a plant growth by using 3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide as an active ingredient as an active ingredient for accelerating a plant growth.
3. The method for accelerating a plant growth according to claim 1, wherein the method is for seed treatment.
4. A method for growing vigourous seedlings by using a compound represented by formula (1) as an active ingredient for growing vigourous seedlings:
wherein R1 and R2 each independently represent a C1-4 alkyl group; Y represents a hydrogen atom, a halogeno group, a C1-4 alkyl group, or a C1-4 haloalkyl group; each R3 independently represents a halogeno group, a cyano group, a nitro group, a C1-4 alkyl group, or a C1-4 haloalkyl group; and n represents the number of R3 and is an integer of 0 to 6.
5. A method for growing vigourous seedlings by using 3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide as an active ingredient as an active ingredient for growing vigourous seedlings.
6. The method for growing vigourous seedlings according to claim 4, wherein the method is for seed treatment.
7. The method for accelerating a plant growth according to claim 2, wherein the method is for seed treatment.
8. The method for growing vigourous seedlings according to claim 5, wherein the method is for seed treatment.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. A method of culturing mononuclear cells, comprising:
isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
culturing the cells in a culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells.
2. The method of claim 1, wherein the cells are selected from the group consisting of CD34-, CD14-, CD11-, CD11b-, CD13-, CD64- and CD68-positive cells and endothelial cells.
3. The method of claim 1, wherein the cells are isolated from blood in veins, capillaries, arteries, umbilical cord or placenta, or from bone marrow, spleen, lymph nodes, peritoneal space, pleural space, lymph, veins, arteries, or capillaries, or from connective tissue fluid.
4. The method of claim 1, wherein the culture medium comprises one or more growth factors for endothelial cells.
5. The method of claim 4, wherein the growth factors are selected from the group consisting of growth factors influencing differentiation, survival, migration and vascularization.
6. The method of claim 1, wherein the growth factors are selected from the group consisting of ECGF, FGF, FGF, ECAF, IGF-1; IGF-2; Sl-3; EGF; SCF, TGF, Tie-2-ligands, stromal derived Factor-1, GM-CSF, G-CSF, M-CSF, Sl-4, Sl-1, CSF-1, Sl-8, PDGF, TFN, oncostatin M, BG1, platelet derived endothelial cell growth factor, TNF, angiogenin, pleiotrophin, VEGF, VEGF-B, VEGF-C, VEGF-D, neuropilin, and Flt-3 ligand.
7. A method of making cells capable of expressing a biologically active protein, comprising:
isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
culturing the cells in a culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells;
optionally, before or after culturing the cells, immortalizing the cells; and
transfecting the cells with a nucleic acid construct comprising a gene for the biologically active protein.
8. The method of claim 7, wherein the cells are selected from the group consisting of CD34-, CD14-, CD11-, CD11b-, CD13-, CD64- and CD68-positive cells and endothelial cells.
9. The method of claim 7, wherein the cells are isolated from blood in veins, capillaries, arteries, umbilical cord or placenta, or from bone marrow, spleen, lymph nodes, peritoneal space, pleural space, lymph, veins, arteries, or capillaries, or from connective tissue fluid.
10. The method of claim 7, wherein the culture medium comprises one or more growth factors for endothelial cells
11. The method of claim 10, wherein the growth factors are selected from the group consisting of growth factors influencing differentiation, survival, migration and vascularization.
12. The method of claim 7, wherein the cells are immortalized by a process selected from the group consisting of transforming the cells with an exogenous oncogene; activating an endogenous oncogene; and inactivating an endogenous suppressor gene.
13. The method of claim 12, wherein the exogenous oncogene is linked to an endothelial cell-specific promoter which controls transcription of the oncogene.
14. The method of claim 12, wherein the endogenous suppressor gene is inactivated upon expression of a nucleotide sequence linked to an endothelial cell specific promoter which controls transcription of the nucleotide sequence.
15. The method of claim 7, wherein the biologically active protein is selected from the group consisting of cytokines, chemokines, and growth factors; receptors for cytokines, chemokines and growth factors; proteins having antiproliferative or cytostatic or apoptotic action; antibodies; antibody fragments; angiogenesis inhibitors; peptide hormones; clotting factors; clotting inhibitors; fibrinolytic proteins, peptides or proteins acting on the blood circulation; blood plasma proteins; and antigens of infective agents, cells or tumors, wherein the antigens trigger an immune response.
16. The method of claim 7, wherein the biologically active protein is an enzyme which cleaves a precursor of a drug into a drug.
17. The method of claim 7, wherein the biologically active protein is a ligand-active compound fusion protein or a ligand-enzyme fusion protein, wherein the ligand is selected from the group consisting of cytokines, growth factors, antibodies, antibody fragments, peptide hormones, mediators, cell adhesion proteins and LDL receptor-binding proteins.
18. The method of claim 7, wherein the nucleic acid construct comprises a promoter operably linked to the gene for the biologically active protein.
19. The method of claim 18, wherein the promoter operates cell-specifically, cell cycle specifically, virus specifically, metabolically or by hypoxia.
20. The method of claim 18, wherein the promoter is inducible.
21. The method of claim 7, wherein the nucleic acid construct comprises at least two promoters operably linked to the gene for the biologically active protein, which promoters may be the same or different.
22. A method of effecting gene therapy of a disorder, comprising:
administering to a patient in need thereof a therapeutically effective amount of cells obtained by
isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
culturing the cells in a culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells;
optionally, before or after culturing the cells, immortalizing the cells; and
transfecting the cells with a nucleic acid construct comprising a gene for a biologically active protein useful in the prophylaxis or therapy of the disorder.
23. The method of claim 22, wherein the biologically active protein is selected from the group consisting of cytokines, chemokines, and growth factors; receptors for cytokines, chemokines and growth factors; proteins having antiproliferative or cytostatic or apoptotic action; antibodies; antibody fragments; angiogenesis inhibitors; peptide hormones; clotting factors; clotting inhibitors; fibrinolytic proteins, peptides or proteins acting on the blood circulation; blood plasma proteins; and antigens of infective agents, cells or tumors, wherein the antigens trigger an immune response.
24. The method of claim 22, wherein the biologically active protein is an enzyme which cleaves a precursor of a drug into a drug.
25. The method of claim 22, wherein the biologically active protein is a ligand-active compound fusion protein or a ligand-enzyme fusion protein, wherein the ligand is selected from the group consisting of cytokines, growth factors, antibodies, antibody fragments, peptide hormones, mediators, cell adhesion proteins and LDL receptor-binding proteins.
26. The method of claim 22, wherein the cells are administered externally, orally, intravesically, nasally, intrabronchially, subcutaneously, into the gastrointestinal tract, or are injected into an organ, into a body cavity, into musculature, or into blood circulation.
27. The method of claim 22, wherein the disorder is selected from the group consisting of tumors, leukemias, autoimmune disorders, allergies, arthritides, inflammations, organ rejections, transplant-host reactions, blood clotting disorders, circulation disorders, anemia, infections, hormone disorders and central nervous system (CNS) damage.
28. A method of endothelializing injured vessels, comprising,
administering to a patient in need thereof a therapeutically effective amount of cells obtained by
isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
culturing the cells in a culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells; and
optionally, before or after culturing the cells, immortalizing the cells.
29. A cell obtainable by:
(a) isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal; and
(b) culturing the mononuclear cells in a cell culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells.
30. A pharmaceutical composition comprising the cell of claim 29 and a pharmaceutically acceptable vehicle, carrier, or diluent.
31. A cell for use in gene therapy, obtainable by
(a) isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
(b) culturing the mononuclear cells in a cell culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells;
(c) optionally, before or after culturing the cells, immortalizing the cells by a process selected from the group consisting of transforming the cells with an exogenous oncogene; activating an endogenous oncogene; and inactivating an endogenous suppressor gene; and
(d) transfecting the cells with a nucleic acid construct comprising a gene coding for a biologically active protein, wherein the nucleic acid construct optionally comprises one or more promoters for expressing the gene for the biologically active protein cell-specifically, cell cycle-specifically, virus-specifically, metabolically or by hypoxia.
32. A pharmaceutical composition comprising the cell of claim 31 and a pharmaceutically acceptable vehicle, carrier, or diluent.

1. A method comprising:
during initial recording of a TV program, deriving a temporary thumbnail representative of the TV program; and
subsequently generating a permanent thumbnail representative of the recorded TV program.
2. A method as described in claim 1, wherein the deriving comprises forming the temporary thumbnail based on a video frame from a beginning portion of the TV program.
3. A method as described in claim 1, wherein the deriving comprises forming the temporary thumbnail based on a first non-black video frame in the TV program.
4. A method as described in claim 1, wherein the generating comprises:
analyzing the recorded TV program;
selecting a representative video frame from the recorded TV program based on the analysis; and
forming the permanent thumbnail based on the representative video frame.
5. A method as described in claim 1, further comprising presenting the temporary thumbnail within a user interface until the permanent thumbnail is generated, and thereafter presenting the permanent thumbnail within the user interface instead of the temporary thumbnail.
6. A method as described in claim 1, further comprising presenting plural thumbnails within a user interface that lists recorded TV programs.
7. A method as described in claim 1, further comprising:
presenting plural thumbnails within a user interface; and
enabling a user to browse recorded TV programs by navigating the plural thumbnails.
8. A method as described in claim 1, further comprising caching at least one of the temporary thumbnail or the permanent thumbnail.
9. A method as described in claim 1, wherein at least one of the temporary thumbnail or the permanent thumbnail is dynamic.
10. A method as described in claim 1, further comprising:
associating the temporary thumbnail and the permanent thumbnail with a content rating that is subject to a preference setting;
presenting the temporary thumbnail and the permanent thumbnail in an event that the preference setting for the associated content rating permits viewing; and
preventing presentation of the temporary thumbnail and the permanent thumbnail in an event that the preference setting for the associated content rating does not permit viewing.
11. A method comprising:
creating a thumbnail that is representative of recorded video content; and
determining whether to present the thumbnail depending upon a rating of the recorded video content.
12. A method as described in claim 11, wherein the thumbnail is dynamic.
13. A method as described in claim 11, wherein the creating comprises forming the thumbnail based on a video frame from the recorded video content.
14. A method as described in claim 11, further comprising presenting a generic image instead of the thumbnail in an event that the thumbnail is determined, based on the rating, not to be presented.
15. A computer-readable media comprising computer-executable instructions that, when executed, direct a device to:
derive, during initial recording of a TV program, a temporary thumbnail from a video frame extracted from an early portion of the TV program;
present the temporary thumbnail in a user interface as an identifier of the TV program;
generate, after the initial recording of the TV program, a permanent thumbnail from a video frame selected from the TV program;
present the permanent thumbnail, instead of the temporary thumbnail, in the user interface as an identifier of the TV program.
16. A computer-readable media as recited in claim 15, further comprising computer-executable instructions that, when executed, direct a device to:
present plural thumbnails within the user interface; and
enable a user to browse the TV programs by navigating the plural thumbnails.
17. A computer-readable media as recited in claim 15, further comprising computer-executable instructions that, when executed, direct a device to cache at least one of the temporary thumbnail or the permanent thumbnail.
18. A computer-readable media as recited in claim 15, further comprising computer-executable instructions that, when executed, direct a device to:
associate the temporary thumbnail and the permanent thumbnail with a content rating that is subject to a preference setting; and
prevent presentation of the temporary thumbnail and the permanent thumbnail in an event that the preference setting for the associated content rating does not permit viewing.
19. A device comprising:
a storage medium to store the TV program;
a processor; and
the computer-readable media as recited in claim 15, operatively coupled to the processor so that when the processor executes the computer-executable instructions, the device derives the temporary thumbnail and generates the permanent thumbnail from the TV program stored in the storage medium.
20. A device comprising:
a recorder to record one or more TV programs onto a recording medium;
a thumbnail generator to form a first thumbnail representative of a TV program as the TV program is initially being recorded and to form a second thumbnail representative of the TV program sometime after the first thumbnail is formed; and
a user interface to present one of the first thumbnail or the second thumbnail as an identifier of the TV program.
21. A device as recited in claim 20, wherein the thumbnail generator forms the first thumbnail from a video frame from a beginning portion of the TV program.
22. A device as recited in claim 20, wherein the thumbnail generator forms the first thumbnail from a first non-black video frame in the TV program.
23. A device as recited in claim 20, wherein the thumbnail generator forms the second thumbnail by analyzing the recorded TV program, selecting a representative video frame from the recorded TV program based on the analysis, and deriving the second thumbnail from the representative video frame.
24. A device as recited in claim 20, wherein the user interface presents the first thumbnail until the second thumbnail is formed, and thereafter presents the second thumbnail instead of the first thumbnail.
25. A device as recited in claim 20, wherein the user interface presents plural thumbnails and enables a user to browse recorded TV programs by navigating the plural thumbnails.
26. A device as recited in claim 20, further comprising a cache to store the first thumbnail and the second thumbnail.
27. A device as recited in claim 20, further comprising a data structure to associate the first and second thumbnails with content ratings, wherein the user interface presents the first and second thumbnails in an event that a preference setting for the content rating permits viewing and the prevents presentation of the first and second thumbnails in an event that the preference setting for the content rating does not permit viewing.
28. A device comprising:
means for deriving, during initial recording of a TV program, a temporary thumbnail representative of the TV program; and
means for subsequently generating a permanent thumbnail representative of the recorded TV program.
29. A device as described in claim 28, wherein the deriving means comprises means for forming the temporary thumbnail based on a video frame from a beginning portion of the TV program.
30. A device as described in claim 28, wherein the deriving means comprises means for forming the temporary thumbnail based on a first non-black video frame in the TV program.
31. A device as described in claim 28, wherein the generating means comprises means for analyzing the recorded TV program, selecting a representative video frame from the recorded TV program based on the analysis, and forming the permanent thumbnail based on the representative video frame.
32. A device as described in claim 28, further comprising means for presenting the temporary thumbnail until the permanent thumbnail is generated, and thereafter presenting the permanent thumbnail instead of the temporary thumbnail.
33. A device as described in claim 28, further comprising:
means for presenting plural thumbnails; and
means for enabling a user to browse recorded TV programs by navigating the plural thumbnails.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. A vaso-occlusive device for treating a vascular malformation, comprising:
an implantable body defining a volume and dimensions suited for implantation at a targeted site in the patient’s vasculature; and
an electrical charge source carried by the said body capable of exposing a selected charge to endovascular media after implantation.
2. The device of claim 1 wherein the electrical charge source comprises a volume of electroactive particles carried by portions of said implantable body.
3. The device of claim 4 wherein said volume of electroactive particles is carried in at least one substantially thin layer around said implantable body.
4. The device of claim 4 wherein said volume of electroactive particles is carried in an interior layer of said implantable body.
5. The device of claim 4 further comprising an exposed conductive element coupled to said volume of electroactive particles.
6. The device of claim 1 wherein the implantable body comprises at least one elongate wire-like member for deformable placement is an aneurysm sac.
7. The device of claim 1 wherein the implantable body comprises a plurality of wire-like members forming a three-dimensional structure for placement is an aneurysmal sac.
8. The device of claim 1 wherein the implantable body is of shape memory material having a first linear or collapsed shape for disposition in the guide wire lumen of a catheter and a second expanded shape for disposition in an aneurysm and said implantable body has first and second end portions that are detachably coupled to first and second guide members.
9. A vaso-occlusive method, comprising the steps of:
implanting an implant body in a targeted site in a patient’s vasculature, wherein the implant body carries a self-contained electrical charge source; and
exposing body media within the targeted site to a selected electrical charge thereby enhancing the formation of thrombus in the targeted site.
10. The vaso-occlusive method of claim 9 wherein the electrical charge is positive.
11. The vaso-occlusive method of claim 9 wherein the electrical charge is negative.
12. The vaso-occlusive method of claim 9 wherein the electrical charge is both positive and negative thereby causing current flow in the endovascular media.
13. A vaso-occlusive device for treating a vascular malformation, comprising:
an implant body defining a length and cross-section suitable for placement in a vascular malformation; and
a voltage source carried within the implantable member.
14. The vaso-occlusive device of claim 13 wherein the voltage source comprises an anode and a cathode of electroactive compositions and a separator element disposed therebetween.
15. The vaso-occlusive device of claim 14 wherein said electroactive compositions comprise nanoparticles.
16. The vaso-occlusive device of claim 15 wherein said nanoparticles have an average cross-section ranging from about 1 nm to 250 nm.
17. The vaso-occlusive device of claim 13 further comprising a first conductive material coupled to said anode composition and exposed to an exterior of the body.
18. The vaso-occlusive device of claim 13 further comprising a second conductive material coupled to said cathode composition and exposed to an exterior of the body.
19. The vaso-occlusive device of claim 13 wherein the voltage source provides from about 0.01 to 5 volts.
20. The vaso-occlusive device of claim 13 further comprising;
a detachable coupling wherein said vaso-occlusive device has a first end surface and a guide member has a second end surface, the first and second surfaces adhered together by a bond matrix;
wherein the guide member comprises an optic fiber; and
wherein the bond matrix carries a volume of chromophore particles that thermoelastically expand upon photoabsorption of a selected wavelength delivered through the optic fiber to propagate a bi-polar stress wave within the bond matrix.